Shawn Tomasello
CIK 1617239 · Chief Commercial Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$70.7K
Companies
10
Total Filings
52
Lifetime Open-Market Net
-$990.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FDMT | Director | — | $9.85 | — | $0 | 6 | 2026-06-18 |
| CABA | Director | 22,725 | $2.73 | $62.0K | $50.3K | 6 | 2026-06-10 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 3,043 | $9.81 | $29.9K | $0 | 4 | 2024-06-07 |
| Gamida Cell Ltd. (GMDA) Delisted | Director | 241,977 | $0.03 | $7.9K | $15.0K | 7 | 2024-02-02 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | — | $1.48 | — | $0 | 4 | 2023-06-01 |
| URGN | Director | — | $40.88 | — | $0 | 3 | 2021-06-09 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 4 | 2020-09-28 |
| ABEO | Director | 1,438 | $6.02 | $8.7K | $0 | 1 | 2020-05-22 |
| Diplomat Pharmacy, Inc. (DPLO) Delisted | Director | 33,259 | — | — | -$51.1K | 8 | 2020-02-10 |
| Kite Pharma, Inc. (KITE) Delisted | Chief Commercial Officer | 61,068 | — | — | -$1.00M | 4 | 2017-09-27 |
Recent Filings · Page 4 of 6
52 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-08 | Principia Biopharma Inc. (PRNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-22 | ABEO | Grant (A) | +35,938 | $0 | EDGAR |
| 2020-02-10 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Mixed | −44,537 | -$178.1K | EDGAR |
| 2019-10-04 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Sell (S) | −859 | -$4.2K | EDGAR |
| 2019-09-04 | Principia Biopharma Inc. (PRNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-08-30 | Principia Biopharma Inc. (PRNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-05 | URGN | Grant (A) | — | $0 | EDGAR |
| 2019-06-05 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Mixed | +31,985 | -$6.2K | EDGAR |
| 2018-10-03 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Grant (A) | +2,275 | $0 | EDGAR |
| 2018-06-05 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Mixed | +1,974 | -$40.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.